Category | Dose Constraint |
---|---|
Bladder-CTV D50 | 65 Gy |
Bladder-CTV D70 | 40 Gy |
Rectum D35 | 65 Gy |
Rectum D55 | 40 Gy |
Right Femoral Head D10 | 50 Gy |
Left Femoral Head D10 | 50 Gy |
Category | 6 MV Mean ± SDOM | 10 MV Mean ± SDOM | Percent Increase | Power | |
---|---|---|---|---|---|
Bladder-CTV D50 | 32.5 ± 4.3 Gy | 29.7 ± 3.9 Gy | −8.62% | 0.013 | 0.79 |
Bladder-CTV D70 | 18.5 ± 3.7 Gy | 16.2 ± 3.2 Gy | −12.4% | 0.011 | 0.81 |
Rectum D35 | 49.5 ± 3.3 Gy | 46.8 ± 3.9 Gy | −5.45% | 6.6 × 10-3 | 0.88 |
Rectum D55 | 28.5 ± 2.7 Gy | 26.7 ± 2.7 Gy | −6.32% | 0.023 | 0.68 |
Right Femoral Head D10 | 34.12 ± 0.86 Gy | 29.80 ± 0.99 Gy | −12.66% | 1.2 × 10-4 | 1.0 |
Left Femoral Head D10 | 32.74 ± 0.94 Gy | 29.4 ± 1.1 Gy | −10.20% | 8.3 × 10-5 | 1.0 |
CTV Min Dose | 65.53 ± 0.38 Gy | 65.29 ± 0.21 Gy | −0.3662% | 0.41 | 0.12 |
CTV Max Dose | 71.01 ± 0.37 Gy | 70.53 ± 0.31 Gy | −0.6760% | 0.10 | 0.37 |
CTV Mean Dose | 68.30 ± 0.29 Gy | 67.68 ± 0.27 Gy | −0.9078% | 0.019 | 0.72 |
CTV Percent Volume Covered by the 95% Isodose Line | 100% | 100% | 0% | N/A | N/A |
PTV Min Dose | 64.42 ± 0.29 Gy | 64.42 ± 0.29 Gy | 0% | 0.10 | 0.37 |
PTV Max Dose | 71.78 ± 0.29 Gy | 71.76 ± 0.33 Gy | −0.02786% | 0.94 | 0.051 |
PTV Mean Dose | 68.39 ± 0.38 Gy | 67.94 ± 0.28 Gy | −0.6580% | 0.063 | 0.47 |
PTV Percent Volume Covered by the 95% Isodose Line | 100% | 100% | 0% | N/A | N/A |
Body V5 | (27.0 ± 1.0)% | (26.5 ± 1.0)% | −1.85% | 2.2 × 10-3 | 0.96 |
Global Max Dose | 71.80 ± 0.38 Gy | 71.76 ± 0.33 Gy | −0.05571% | 0.89 | 0.052 |
Arc 1 Monitor Units | 325 ± 17 MU | 311.8 ± 9.8 MU | −4.06% | 0.41 | 0.12 |
Arc 2 Monitor Units | 330 ± 15 MU | 312 ± 10 MU | −5.5% | 0.19 | 0.24 |
Conformity Index | 1.127 ± 0.013 | 1.091 ± 0.015 | −3.194% | 6.8 × 10-4 | 0.99 |
Integral Dose | 207 ± 12 Gy-L | 191 ± 11 Gy-L | −7.73% | 1.1 × 10-5 | 1.0 |